Fluorescent PARP Inhibitors Applied to Intracranial Glioblastoma: Accumulation and Persistence in Vivo

Zhe Gao; Zhen Yang; Zheng Li; Kevin Burgess

doi:10.1021/acsmedchemlett.1c00712

Fluorescent PARP Inhibitors Applied to Intracranial Glioblastoma: Accumulation and Persistence in Vivo

Zhe Gao, Zhen Yang, Zheng Li, Kevin Burgess

Academic Institute

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Rucaparib-containing fluorescent probes (1-3) inhibit PARP1 in cell models. One of these (1) was tested in a murine model and shown to permeate into implanted intracranial glioblastoma tumors and persist there for at least 24 h.

Original language	English (US)
Pages (from-to)	911-915
Number of pages	5
Journal	ACS Medicinal Chemistry Letters
Volume	13
Issue number	6
DOIs	https://doi.org/10.1021/acsmedchemlett.1c00712
State	Published - Jun 9 2022

Keywords

MHI-148
PARP inhibitor
cyanine
glioblastoma
rucaparib

ASJC Scopus subject areas

Biochemistry
Drug Discovery
Organic Chemistry

Access to Document

10.1021/acsmedchemlett.1c00712

Cite this

@article{5576a2ae8feb4e3fad2abc1c4468253e,

title = "Fluorescent PARP Inhibitors Applied to Intracranial Glioblastoma: Accumulation and Persistence in Vivo",

abstract = "Rucaparib-containing fluorescent probes (1-3) inhibit PARP1 in cell models. One of these (1) was tested in a murine model and shown to permeate into implanted intracranial glioblastoma tumors and persist there for at least 24 h.",

keywords = "MHI-148, PARP inhibitor, cyanine, glioblastoma, rucaparib",

author = "Zhe Gao and Zhen Yang and Zheng Li and Kevin Burgess",

note = "Publisher Copyright: {\textcopyright} 2022 American Chemical Society.",

year = "2022",

month = jun,

day = "9",

doi = "10.1021/acsmedchemlett.1c00712",

language = "English (US)",

volume = "13",

pages = "911--915",

journal = "ACS Medicinal Chemistry Letters",

issn = "1948-5875",

publisher = "American Chemical Society",

number = "6",

}

TY - JOUR

T1 - Fluorescent PARP Inhibitors Applied to Intracranial Glioblastoma

T2 - Accumulation and Persistence in Vivo

AU - Gao, Zhe

AU - Yang, Zhen

AU - Li, Zheng

AU - Burgess, Kevin

PY - 2022/6/9

Y1 - 2022/6/9

N2 - Rucaparib-containing fluorescent probes (1-3) inhibit PARP1 in cell models. One of these (1) was tested in a murine model and shown to permeate into implanted intracranial glioblastoma tumors and persist there for at least 24 h.

AB - Rucaparib-containing fluorescent probes (1-3) inhibit PARP1 in cell models. One of these (1) was tested in a murine model and shown to permeate into implanted intracranial glioblastoma tumors and persist there for at least 24 h.

KW - MHI-148

KW - PARP inhibitor

KW - cyanine

KW - glioblastoma

KW - rucaparib

UR - http://www.scopus.com/inward/record.url?scp=85130415703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130415703&partnerID=8YFLogxK

U2 - 10.1021/acsmedchemlett.1c00712

DO - 10.1021/acsmedchemlett.1c00712

M3 - Article

AN - SCOPUS:85130415703

SN - 1948-5875

VL - 13

SP - 911

EP - 915

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

IS - 6

ER -

Fluorescent PARP Inhibitors Applied to Intracranial Glioblastoma: Accumulation and Persistence in Vivo

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this